糖尿病视网膜病变的新型药物疗法：现状与展望？
Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?
作者信息
Das Arup, McGuire Paul G, Monickaraj Finny
机构信息
Department of Surgery, Division of Ophthalmology, University of New Mexico School of Medicine; Department of Surgery, New Mexico VA Health Care System; Department of Cell Biology and Physiology, University of New Mexico, Albuquerque, New Mexico, USA.
出版信息
Indian J Ophthalmol. 2016 Jan;64(1):4-13. doi: 10.4103/0301-4738.178154.
The blood-retinal barrier (BRB) alteration is the hallmark feature of diabetic retinopathy. Vascular endothelial growth factor (VEGF) is a potent vasopermeability factor that has been implicated in the pathogenesis of BRB alteration. Inflammation also plays a crucial role in this process with involvement of several chemokines and cytokines. Multiple anti-VEGF drugs are widely used as in the treatment of diabetic macular edema (DME) as well as proliferative diabetic retinopathy. Several clinical trials have proved the beneficial effects of these drugs in improvement of vision and prevention of vision loss. However, the response to anti-VEGF drugs in DME is not complete in a significant number of patients. The effect seems transient in this latter group, and many patients do not show complete resolution of fluid. Potential novel therapies targeting molecules beyond VEGF are being developed and examined in clinical trials.
血视网膜屏障（BRB）改变是糖尿病视网膜病变的标志性特征。血管内皮生长因子（VEGF）是一种强效的血管通透性因子，与BRB改变的发病机制有关。炎症在这一过程中也起着关键作用，涉及多种趋化因子和细胞因子。多种抗VEGF药物广泛用于治疗糖尿病性黄斑水肿（DME）以及增殖性糖尿病视网膜病变。多项临床试验已证明这些药物在改善视力和预防视力丧失方面的有益作用。然而，相当一部分患者对DME中的抗VEGF药物反应并不完全。在后一组患者中，这种效果似乎是短暂的，许多患者的积液并未完全消退。针对VEGF以外分子的潜在新型疗法正在临床试验中进行开发和研究。
Zotero 插件